Hepatitis news and hepatitis widget

A new, independently-conducted study being presented at AASLD shows that PEGASYS(R) (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.(1) Comparing Today's Standard Treatment Regimens: The Milan Safety Tolerability Study Prof. Colombo, Head of the 1st Division of Gastroenterology and A.M.